Loading…

Porous orbital implant after enucleation in retinoblastoma patients: indications and complications

This study aims to identify risk factors associated with complications in retinoblastoma patients following primary and secondary enucleations with porous implant placement. A retrospective case-control study was performed between 2010 and 2015. Data pertaining to subjects' demographics, medica...

Full description

Saved in:
Bibliographic Details
Published in:Orbit (Amsterdam) 2018-11, Vol.37 (6), p.438-443
Main Authors: Lang, Paul, Kim, Jonathan W., McGovern, Kathleen, Reid, Mark W., Subramanian, Krishnan, Murphree, A. Linn, Berry, Jesse L.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c468t-a197e722e118a2ce8f5919deb372bcc43def957cea2aff8e7532d4712b695dca3
cites cdi_FETCH-LOGICAL-c468t-a197e722e118a2ce8f5919deb372bcc43def957cea2aff8e7532d4712b695dca3
container_end_page 443
container_issue 6
container_start_page 438
container_title Orbit (Amsterdam)
container_volume 37
creator Lang, Paul
Kim, Jonathan W.
McGovern, Kathleen
Reid, Mark W.
Subramanian, Krishnan
Murphree, A. Linn
Berry, Jesse L.
description This study aims to identify risk factors associated with complications in retinoblastoma patients following primary and secondary enucleations with porous implant placement. A retrospective case-control study was performed between 2010 and 2015. Data pertaining to subjects' demographics, medical history, clinical, and pathological findings, implant characteristics and complications were collected. The analysis included 103 eyes of 101 patients age 27.8 ± 21.9 months undergoing enucleation for retinoblastoma. Postoperatively, 19/103 (18%) eyes developed exposure, extrusion, or hematoma requiring subsequent surgery. Exposure was the most common postoperative complication (12/19, 63%). Age at enucleation 24 months or younger, Hispanic ethnicity, female gender, and intravenous chemotherapy prior to enucleation were associated with increased odds of implant complications. In contrast, patients who were given intravitreal melphalan (IM), subtenons carboplatin (SC), or external beam radiation therapy (EBRT) did not demonstrate an increased risk of complications. In this cohort of retinoblastoma patients undergoing primary or secondary enucleation with porous implants, implant exposure was the most common postoperative complication. Our findings suggest that female gender, Hispanic ethnicity, age at enucleation 24 months or younger, and intravenous chemotherapy prior to enucleation may increase the risk of complications.
doi_str_mv 10.1080/01676830.2018.1440605
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_29461921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2007116820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-a197e722e118a2ce8f5919deb372bcc43def957cea2aff8e7532d4712b695dca3</originalsourceid><addsrcrecordid>eNp9kU-PFCEQxYnRuOPqR9D00UuPQNNAezBuNv5LNtGDnkk1XSiGhhEYzX57GWdmoxdPldT71atKPUKeMrplVNMXlEkl9UC3nDK9ZUJQScd7ZMOUEP3YkPtkc2D6A3RBHpXynVI6aEEfkgs-CckmzjZk_pRy2pcu5dlXCJ1fdwFi7cBVzB3GvQ0I1afY-dhlrD6mOUCpaYVu1wSMtbxs2uLtH6x0EJfOpmZz7jwmDxyEgk9O9ZJ8efvm8_X7_ubjuw_XVze9FVLXHtikUHGOjGngFrUbJzYtOA-Kz9aKYUE3jcoicHBOoxoHvgjF-CyncbEwXJJXR9_dfl5xse20DMHssl8h35oE3vyrRP_NfE0_jZRsGKVoBs9PBjn92GOpZvXFYmgPwfYjwylVjEnNaUPHI2pzKiWju1vDqDnkY875mEM-5pRPm3v29413U-dAGvD6CPjoUl7hV8phMRVuQ8ouQ7S-mOH_O34DGPOjUg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007116820</pqid></control><display><type>article</type><title>Porous orbital implant after enucleation in retinoblastoma patients: indications and complications</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Lang, Paul ; Kim, Jonathan W. ; McGovern, Kathleen ; Reid, Mark W. ; Subramanian, Krishnan ; Murphree, A. Linn ; Berry, Jesse L.</creator><creatorcontrib>Lang, Paul ; Kim, Jonathan W. ; McGovern, Kathleen ; Reid, Mark W. ; Subramanian, Krishnan ; Murphree, A. Linn ; Berry, Jesse L.</creatorcontrib><description>This study aims to identify risk factors associated with complications in retinoblastoma patients following primary and secondary enucleations with porous implant placement. A retrospective case-control study was performed between 2010 and 2015. Data pertaining to subjects' demographics, medical history, clinical, and pathological findings, implant characteristics and complications were collected. The analysis included 103 eyes of 101 patients age 27.8 ± 21.9 months undergoing enucleation for retinoblastoma. Postoperatively, 19/103 (18%) eyes developed exposure, extrusion, or hematoma requiring subsequent surgery. Exposure was the most common postoperative complication (12/19, 63%). Age at enucleation 24 months or younger, Hispanic ethnicity, female gender, and intravenous chemotherapy prior to enucleation were associated with increased odds of implant complications. In contrast, patients who were given intravitreal melphalan (IM), subtenons carboplatin (SC), or external beam radiation therapy (EBRT) did not demonstrate an increased risk of complications. In this cohort of retinoblastoma patients undergoing primary or secondary enucleation with porous implants, implant exposure was the most common postoperative complication. Our findings suggest that female gender, Hispanic ethnicity, age at enucleation 24 months or younger, and intravenous chemotherapy prior to enucleation may increase the risk of complications.</description><identifier>ISSN: 0167-6830</identifier><identifier>EISSN: 1744-5108</identifier><identifier>DOI: 10.1080/01676830.2018.1440605</identifier><identifier>PMID: 29461921</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Case-Control Studies ; Chemotherapy ; Child, Preschool ; complications ; exposure ; Eye Enucleation ; Female ; Humans ; Infant ; Intraoperative Complications ; Male ; Orbital Implants ; Polyethylenes ; Porosity ; porous implant ; Postoperative Complications ; Prosthesis Implantation ; Radiotherapy ; Retinal Neoplasms - pathology ; Retinal Neoplasms - surgery ; retinoblastoma ; Retinoblastoma - pathology ; Retinoblastoma - surgery ; Retrospective Studies ; Risk Factors</subject><ispartof>Orbit (Amsterdam), 2018-11, Vol.37 (6), p.438-443</ispartof><rights>2018 Taylor &amp; Francis 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-a197e722e118a2ce8f5919deb372bcc43def957cea2aff8e7532d4712b695dca3</citedby><cites>FETCH-LOGICAL-c468t-a197e722e118a2ce8f5919deb372bcc43def957cea2aff8e7532d4712b695dca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27915,27916</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29461921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lang, Paul</creatorcontrib><creatorcontrib>Kim, Jonathan W.</creatorcontrib><creatorcontrib>McGovern, Kathleen</creatorcontrib><creatorcontrib>Reid, Mark W.</creatorcontrib><creatorcontrib>Subramanian, Krishnan</creatorcontrib><creatorcontrib>Murphree, A. Linn</creatorcontrib><creatorcontrib>Berry, Jesse L.</creatorcontrib><title>Porous orbital implant after enucleation in retinoblastoma patients: indications and complications</title><title>Orbit (Amsterdam)</title><addtitle>Orbit</addtitle><description>This study aims to identify risk factors associated with complications in retinoblastoma patients following primary and secondary enucleations with porous implant placement. A retrospective case-control study was performed between 2010 and 2015. Data pertaining to subjects' demographics, medical history, clinical, and pathological findings, implant characteristics and complications were collected. The analysis included 103 eyes of 101 patients age 27.8 ± 21.9 months undergoing enucleation for retinoblastoma. Postoperatively, 19/103 (18%) eyes developed exposure, extrusion, or hematoma requiring subsequent surgery. Exposure was the most common postoperative complication (12/19, 63%). Age at enucleation 24 months or younger, Hispanic ethnicity, female gender, and intravenous chemotherapy prior to enucleation were associated with increased odds of implant complications. In contrast, patients who were given intravitreal melphalan (IM), subtenons carboplatin (SC), or external beam radiation therapy (EBRT) did not demonstrate an increased risk of complications. In this cohort of retinoblastoma patients undergoing primary or secondary enucleation with porous implants, implant exposure was the most common postoperative complication. Our findings suggest that female gender, Hispanic ethnicity, age at enucleation 24 months or younger, and intravenous chemotherapy prior to enucleation may increase the risk of complications.</description><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Case-Control Studies</subject><subject>Chemotherapy</subject><subject>Child, Preschool</subject><subject>complications</subject><subject>exposure</subject><subject>Eye Enucleation</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Intraoperative Complications</subject><subject>Male</subject><subject>Orbital Implants</subject><subject>Polyethylenes</subject><subject>Porosity</subject><subject>porous implant</subject><subject>Postoperative Complications</subject><subject>Prosthesis Implantation</subject><subject>Radiotherapy</subject><subject>Retinal Neoplasms - pathology</subject><subject>Retinal Neoplasms - surgery</subject><subject>retinoblastoma</subject><subject>Retinoblastoma - pathology</subject><subject>Retinoblastoma - surgery</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><issn>0167-6830</issn><issn>1744-5108</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kU-PFCEQxYnRuOPqR9D00UuPQNNAezBuNv5LNtGDnkk1XSiGhhEYzX57GWdmoxdPldT71atKPUKeMrplVNMXlEkl9UC3nDK9ZUJQScd7ZMOUEP3YkPtkc2D6A3RBHpXynVI6aEEfkgs-CckmzjZk_pRy2pcu5dlXCJ1fdwFi7cBVzB3GvQ0I1afY-dhlrD6mOUCpaYVu1wSMtbxs2uLtH6x0EJfOpmZz7jwmDxyEgk9O9ZJ8efvm8_X7_ubjuw_XVze9FVLXHtikUHGOjGngFrUbJzYtOA-Kz9aKYUE3jcoicHBOoxoHvgjF-CyncbEwXJJXR9_dfl5xse20DMHssl8h35oE3vyrRP_NfE0_jZRsGKVoBs9PBjn92GOpZvXFYmgPwfYjwylVjEnNaUPHI2pzKiWju1vDqDnkY875mEM-5pRPm3v29413U-dAGvD6CPjoUl7hV8phMRVuQ8ouQ7S-mOH_O34DGPOjUg</recordid><startdate>20181102</startdate><enddate>20181102</enddate><creator>Lang, Paul</creator><creator>Kim, Jonathan W.</creator><creator>McGovern, Kathleen</creator><creator>Reid, Mark W.</creator><creator>Subramanian, Krishnan</creator><creator>Murphree, A. Linn</creator><creator>Berry, Jesse L.</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181102</creationdate><title>Porous orbital implant after enucleation in retinoblastoma patients: indications and complications</title><author>Lang, Paul ; Kim, Jonathan W. ; McGovern, Kathleen ; Reid, Mark W. ; Subramanian, Krishnan ; Murphree, A. Linn ; Berry, Jesse L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-a197e722e118a2ce8f5919deb372bcc43def957cea2aff8e7532d4712b695dca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Case-Control Studies</topic><topic>Chemotherapy</topic><topic>Child, Preschool</topic><topic>complications</topic><topic>exposure</topic><topic>Eye Enucleation</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Intraoperative Complications</topic><topic>Male</topic><topic>Orbital Implants</topic><topic>Polyethylenes</topic><topic>Porosity</topic><topic>porous implant</topic><topic>Postoperative Complications</topic><topic>Prosthesis Implantation</topic><topic>Radiotherapy</topic><topic>Retinal Neoplasms - pathology</topic><topic>Retinal Neoplasms - surgery</topic><topic>retinoblastoma</topic><topic>Retinoblastoma - pathology</topic><topic>Retinoblastoma - surgery</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lang, Paul</creatorcontrib><creatorcontrib>Kim, Jonathan W.</creatorcontrib><creatorcontrib>McGovern, Kathleen</creatorcontrib><creatorcontrib>Reid, Mark W.</creatorcontrib><creatorcontrib>Subramanian, Krishnan</creatorcontrib><creatorcontrib>Murphree, A. Linn</creatorcontrib><creatorcontrib>Berry, Jesse L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Orbit (Amsterdam)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lang, Paul</au><au>Kim, Jonathan W.</au><au>McGovern, Kathleen</au><au>Reid, Mark W.</au><au>Subramanian, Krishnan</au><au>Murphree, A. Linn</au><au>Berry, Jesse L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Porous orbital implant after enucleation in retinoblastoma patients: indications and complications</atitle><jtitle>Orbit (Amsterdam)</jtitle><addtitle>Orbit</addtitle><date>2018-11-02</date><risdate>2018</risdate><volume>37</volume><issue>6</issue><spage>438</spage><epage>443</epage><pages>438-443</pages><issn>0167-6830</issn><eissn>1744-5108</eissn><abstract>This study aims to identify risk factors associated with complications in retinoblastoma patients following primary and secondary enucleations with porous implant placement. A retrospective case-control study was performed between 2010 and 2015. Data pertaining to subjects' demographics, medical history, clinical, and pathological findings, implant characteristics and complications were collected. The analysis included 103 eyes of 101 patients age 27.8 ± 21.9 months undergoing enucleation for retinoblastoma. Postoperatively, 19/103 (18%) eyes developed exposure, extrusion, or hematoma requiring subsequent surgery. Exposure was the most common postoperative complication (12/19, 63%). Age at enucleation 24 months or younger, Hispanic ethnicity, female gender, and intravenous chemotherapy prior to enucleation were associated with increased odds of implant complications. In contrast, patients who were given intravitreal melphalan (IM), subtenons carboplatin (SC), or external beam radiation therapy (EBRT) did not demonstrate an increased risk of complications. In this cohort of retinoblastoma patients undergoing primary or secondary enucleation with porous implants, implant exposure was the most common postoperative complication. Our findings suggest that female gender, Hispanic ethnicity, age at enucleation 24 months or younger, and intravenous chemotherapy prior to enucleation may increase the risk of complications.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>29461921</pmid><doi>10.1080/01676830.2018.1440605</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0167-6830
ispartof Orbit (Amsterdam), 2018-11, Vol.37 (6), p.438-443
issn 0167-6830
1744-5108
language eng
recordid cdi_pubmed_primary_29461921
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Case-Control Studies
Chemotherapy
Child, Preschool
complications
exposure
Eye Enucleation
Female
Humans
Infant
Intraoperative Complications
Male
Orbital Implants
Polyethylenes
Porosity
porous implant
Postoperative Complications
Prosthesis Implantation
Radiotherapy
Retinal Neoplasms - pathology
Retinal Neoplasms - surgery
retinoblastoma
Retinoblastoma - pathology
Retinoblastoma - surgery
Retrospective Studies
Risk Factors
title Porous orbital implant after enucleation in retinoblastoma patients: indications and complications
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T22%3A57%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Porous%20orbital%20implant%20after%20enucleation%20in%20retinoblastoma%20patients:%20indications%20and%20complications&rft.jtitle=Orbit%20(Amsterdam)&rft.au=Lang,%20Paul&rft.date=2018-11-02&rft.volume=37&rft.issue=6&rft.spage=438&rft.epage=443&rft.pages=438-443&rft.issn=0167-6830&rft.eissn=1744-5108&rft_id=info:doi/10.1080/01676830.2018.1440605&rft_dat=%3Cproquest_pubme%3E2007116820%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-a197e722e118a2ce8f5919deb372bcc43def957cea2aff8e7532d4712b695dca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2007116820&rft_id=info:pmid/29461921&rfr_iscdi=true